Gravity Analytica

MediWound to Report Third Quarter 2024 Financial Results

MDWD 11.12.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-26

Name of Upcoming Event:Conference Call and Webcast

Full Press Release SEC Filings Our MDWD Tweets

About Gravity Analytica

Recent Filings

Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time

YAVNE, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2024, on Tuesday, November 26, 2024.

Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates.

Dial-in and call details are as follows:

Conference Call & Webcast Details
Toll-Free:	1-833-630-1956
Israel:	1-80-921-2373
International:	1-412-317-1837
Webcast:	Click HERE

To access the call, participants should dial the applicable telephone number aboveat least 5 minutesprior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.

MediWound’s first drug, NexoBrid^®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx^®, a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx has distinct advantages over the current $360+ million market leader, presenting a unique opportunity for significant market growth.

For more information visitwww.mediwound.comand follow us onLinkedIn.

MediWound Contacts:
Hani Luxenburg	Daniel Ferry
Chief Financial Officer	Managing Director
MediWound Ltd.	LifeSci Advisors, LLC
ir@mediwound.com	daniel@lifesciadvisors.com


Media Contact:
Ellie Hanson
FINN Partners for MediWound
ellie.hanson@finnpartners.com
+1-929-588-2008

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com